SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (569)11/3/2003 6:14:46 PM
From: dalroi  Read Replies (2) | Respond to of 3661
 
ESPR


Bad Esperion data confirmed
11/03/03 04:07 PM ET
(By Adam Feuerstein from Real Money)

I just talked to a source with a copy of the JAMA article mentioned below involving Esperion Therapeutics' (ESPR-Nasdaq) arterial plaque-reducing drug ETC216. And yes, the data is negative.

Without going into a lot of details, the level of arterial plaque reduction in patients given ETC216 compared to patients taking a placebo was NOT statistically significant...